login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
AMNEAL PHARMACEUTICALS INC (AMRX) Stock News
NASDAQ:AMRX -
US03168L1052
-
Common Stock
9.56
USD
+0.01 (+0.1%)
Last: 8/29/2025, 8:06:21 PM
9.56
USD
0 (0%)
After Hours:
8/29/2025, 8:06:21 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
AMRX Latest News, Press Relases and Analysis
All
Press Releases
17 days ago - By: Zacks Investment Research
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?
18 days ago - By: Zacks Investment Research
- Mentions:
BSX
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
26 days ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
a month ago - By: Benzinga
A Peek at Amneal Pharmaceuticals's Future Earnings
a month ago - By: Zacks Investment Research
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why
18 days ago - By: Zacks Investment Research
Here's Why Momentum in Amneal (AMRX) Should Keep going
25 days ago - By: The Motley Fool
Amneal (AMRX) Q2 EPS Jumps 56%
26 days ago - By: Zacks Investment Research
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
26 days ago - By: Zacks Investment Research
- Mentions:
CATX
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
26 days ago - By: Amneal Pharmaceuticals LLC
Amneal Reports Second Quarter 2025 Financial Results
26 days ago - By: Amneal Pharmaceuticals LLC
Amneal Reports Second Quarter 2025 Financial Results
a month ago - By: Zacks Investment Research
- Mentions:
PFE
EXAS
VTRS
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
a month ago - By: Zacks Investment Research
- Mentions:
LLY
NKTR
CRMD
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
a month ago - By: Zacks Investment Research
- Mentions:
TECH
CRMD
GMAB
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
a month ago - By: Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
a month ago - By: Zacks Investment Research
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet
a month ago - By: Amneal Pharmaceuticals LLC
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
a month ago - By: Amneal Pharmaceuticals LLC
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
a month ago - By: Amneal Pharmaceuticals LLC
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
a month ago - By: Amneal Pharmaceuticals LLC
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
2 months ago - By: Yahoo Finance
Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal to Report Second Quarter 2025 Results on August 5, 2025
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal to Report Second Quarter 2025 Results on August 5, 2025
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
2 months ago - By: Amneal Pharmaceuticals LLC
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
3 months ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
3 months ago - By: Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Please enable JavaScript to continue using this application.